NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. reported a fiscal year 2025 net loss of $203.8 million, driven by significant operating expenses of $248.2 million that far exceeded its $22.5 million in revenue. The company generated substantial interest income of $27.6 million and recorded fair value gains on warrants of $22.8 million, partially offsetting operating losses. Cash flow from operations was negative $147.8 million, while investing activities consumed $174.9 million primarily for marketable securities purchases. The company maintains a strong liquidity position with $490.0 million in cash and cash equivalents and total current assets of $675.7 million, supported by $683.4 million in shareholders' equity. Research and development expenses totaled $141.8 million, reflecting continued investment in pharmaceutical development programs.

Key Takeaways